This is a working overview of Gastric juice protein, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-12-24. Anything still debated is marked as such rather than presented as settled.
Within the research literature, the peptide is discussed through several provisional mechanisms, including cytoprotection, modulation of growth factor signaling, and interaction with the nitric oxide system. None of these mechanisms is fully characterized, and no single pathway is universally accepted. Review articles typically note the gap between consistent animal findings and sparse human evidence. The compound is classified as a research chemical rather than an approved pharmaceutical, which shapes how studies are designed, funded, and reported.
BPC-157 is a synthetic pentadecapeptide with the sequence GEPPPGKPADDAGLV, corresponding to a partial fragment of a larger protein detected in human gastric juice. The name derives from the parent protein designation BPC, an abbreviation of body protection compound, with 157 acting as a fraction or batch identifier used by the original investigators. Its molecular weight is approximately 1419 daltons, and the chain contains no unusual residues or disulfide bridges. In the literature it is described as a short, water-soluble fragment rather than a complete natural protein.
Most early work on this peptide originated in the 1990s from a research group in Zagreb, Croatia, relying on animal models and cell cultures. Reported observations included effects on gastrointestinal lesion healing, tendon fibroblast migration, and blood vessel formation under controlled laboratory conditions. These findings come predominantly from rodent studies and in vitro assays rather than from human trials. Controlled human data remain limited, and the degree to which animal results translate to human physiology is an open question rather than a settled fact.
Confirmation of identity and purity relies on standard peptide analysis techniques. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities and serves as the most common purity assay. Mass spectrometry, often coupled to that chromatography step, provides an accurate molecular mass that can be matched against the expected value. Amino acid analysis or sequencing can be added for further confirmation. Because short peptides can be produced by different synthetic routes, laboratories usually report both a chromatographic purity percentage and a mass confirmation rather than a single figure.
BPC-157 is commonly supplied as a lyophilized powder, a freeze-dried solid that is reconstituted before use in laboratory work. As a short peptide, it dissolves readily in water and in aqueous buffer solutions, and stock solutions are typically prepared in water or a mild buffer. The chain contains several proline and acidic residues, which influence how it behaves in solution. Because the solid can take up moisture, weighing and handling are usually performed under low-humidity conditions. Its solubility class is described as freely soluble in water rather than requiring an organic solvent.
Dry powder is generally stored at low temperature, with minus twenty degrees Celsius or colder advised for extended retention. Reconstituted solutions are less stable than the solid form and are normally kept cold and shielded from repeated freeze-thaw cycles. Light exposure is avoided because some peptides degrade under ultraviolet radiation. The exact rate of degradation depends on concentration, pH, and the presence of salts, so a single shelf life does not apply to every preparation. Reported stability figures should be read as indicative of typical handling rather than as universal constants.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C62H98N16O22 | computed for the free peptide |
| Molecular weight | about 1419 Da | monoisotopic mass near 1418.7 |
| Amino acid count | 15 | single chain, no disulfide bonds |
| Solubility | freely soluble in water | also dissolves in saline and phosphate buffer |
| Common synonyms | pentadecapeptide BPC, BPC 157 | fragment notation varies by source |
The sequence contains an unusually high proportion of proline and glycine, which limits regular secondary structure and contributes to solubility in aqueous media. The compound dissolves readily in water and in normal saline. Because it is a peptide, digestive enzymes are expected to break it down if it is swallowed, a consideration that influences the routes of administration used in animal experiments. Detailed conformational data remain limited, and published structural models are largely computational.
BPC 157 is a synthetic peptide built from fifteen amino acids. The letters stand for body protection compound, and the number is a laboratory code rather than a description of any biological feature. Its single-letter sequence is GEPPPGKPADDAGLV, which corresponds to a calculated mass near 1419.5 daltons. The material is produced by solid-phase peptide synthesis and is distributed as a lyophilized powder, not as a purified extract from a natural source.
Early work on this family of molecules examined fractions of human gastric juice, where a larger protein was reported to protect gastrointestinal tissue in animal models. BPC 157 was designed as a shorter, more stable fragment of that protein and then studied on its own. The peptide itself is not a normal dietary component and is not present in the human body in meaningful quantities. Descriptions of its origin therefore refer to the research lineage of a laboratory molecule rather than to an endogenous or nutritional substance.
Published storage guidance follows general peptide practice rather than product-specific studies. The dry powder is typically kept at minus 20 degrees Celsius, away from light and moisture. Once reconstituted, solutions are generally refrigerated and used over days to weeks, because the aqueous environment slowly promotes hydrolysis and oxidation. Long-term data on degradation rates or breakdown products are sparse. Stated shelf lives from different producers vary widely, reflecting the absence of a shared reference standard.
BPC-157 is a synthetic peptide built from fifteen amino acid residues. Its sequence comes from a larger protein fragment that researchers isolated from human gastric juice and described as a body protection compound. The fragment contains glycine, glutamic acid, five prolines, lysine, alanine, two aspartic acids, leucine, and valine. The number 157 in the name refers to the position of the stretch within the parent protein. Material used in laboratories is manufactured rather than extracted from stomach fluid.
The molecule carries 15 residues, a molar mass near 1419.5 g/mol, and the formula C62H98N16O22. Its structure features a proline-rich central region, a pair of adjacent aspartic acid residues, and no cysteine. The absence of cysteine means no disulfide bonds can form, which simplifies refolding and reconstitution. Suppliers usually ship the material as a freeze-dried powder that appears white to off-white. It dissolves readily in water and in saline solutions.
The main chemical liabilities of this sequence are peptide-bond hydrolysis and possible aspartate-related reactions, since the peptide contains aspartic acid residues but no cysteine, methionine, or tryptophan. Absence of those three residues removes the most common oxidation and disulfide pathways from consideration. Studies of related peptides indicate that aspartate isomerisation and aspartimide formation occur most readily at Asp-Gly and Asp-Ala positions, and open questions remain about how quickly those reactions proceed under ordinary laboratory conditions. Storage guidance typically emphasises cool, dry, dark conditions to slow hydrolysis.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry using electrospray or MALDI ionisation. Amino acid analysis and peptide mapping by enzymatic digestion provide additional sequence-level confirmation. Purity is commonly reported as an area percentage from a chromatographic trace, and water content can be measured by Karl Fischer titration. Reported masses may differ by tens of daltons between sources because preparations can contain acetate or trifluoroacetate counterions, and such differences are not by themselves evidence of a different peptide.
BPC-157 is normally distributed as a lyophilised powder that ranges from white to off-white in appearance. The peptide dissolves readily in water, normal saline, and common aqueous buffers, and it is poorly soluble in nonpolar solvents such as hexane or vegetable oils. Lyophilised vials take up moisture if left open, which changes the mass of powder in the container and complicates any later weighing. Because the material is handled in small quantities, static and adhesion to glass or plastic can also cause noticeable losses during transfer.
Analytical results depend on the column, gradient, and detector wavelength chosen by the laboratory, so purity values from different sources are not always directly comparable. Water content, counterion form, and residual trifluoroacetate affect both mass and purity calculations. Microbiological and endotoxin testing are separate from chemical purity and are not covered by a standard chromatographic run. Buyers evaluating a material typically request the full method description rather than a single purity figure.
Lyophilized peptide powder is generally stored at minus twenty degrees Celsius or lower and kept away from light and moisture. Under these conditions degradation is slow, and sealed vials remain stable for extended periods. Once dissolved, the material is less stable, particularly in aqueous buffers near neutral pH, where hydrolysis and oxidation proceed faster. Solutions are usually kept cold and used within days to weeks. Repeated freeze-thaw cycles are avoided because they encourage aggregation.
Offensive realists accept that threatened states usually balance against dangerous foes, however, they maintain that balancing is often inefficient and that this inefficiency provides opportunities for a clever aggressor to take advantage of its adversaries. Buck passing, rather than joining a balancing coalition, is another tactic offensive realists point to when disputing the balance of power theory. Offensive realists believe that internal balancing measures such as increasing defense spending, implementing conscription, are only effective to a certain extent as there are usually significant limits on how many additional resources a threatened state can muster against an aggressor. However, since offensive realists theorize that states are always seeking to maximize their power, states are "effectively engaged in internal balancing all the time".
== Later research == Later research projects conducted by Leeman and her lab were centered around the two peptides, substance P and neurotensin, that she originally isolated, sequenced, and synthesized. Her lab at Boston University has multiple goals regarding these neural peptides, including mapping their distribution within the brain and peripheral nervous system, delineating tracts containing substance P or neurotensin within the central nervous system, determining how substance P and neurotensin are released from neural tissue in vitro and in vivo, and identifying the binding domain of substance P with its receptor.
== Function == Alpha cells function in the maintenance of blood glucose levels. Alpha cells are stimulated to produce glucagon in response to hypoglycemia, epinephrine, amino acids, other hormones, and neurotransmitters.
There are no stable nuclides having an equal number of protons and neutrons in their nuclei with atomic number greater than 20 (i.e. calcium) as can be readily observed from the chart. Nuclei of greater atomic number require an excess of neutrons for stability. The only stable nuclides having an odd number of protons and an odd number of neutrons are hydrogen-2 (deuterium), lithium-6, boron-10, nitrogen-14 and (observationally) tantalum-180m. This is because the mass–energy of such atoms is usually higher than that of their neighbors on the same isobaric chain, so most of them are unstable to beta decay. There are no stable nuclides with mass number 5 or 8. There are stable nuclides with all other mass numbers up to 208 with the exceptions of 147 and 151, which are represented by the very long-lived samarium-147 and europium-151. (Bismuth-209 was found to be radioactive in 2003, but with a half-life of 2.01×1019 years.) With the exception of the pair tellurium-123 and antimony-123, odd mass numbers are never represented by more than one stable nuclide. This is because the mass–energy is a convex function of atomic number, so all nuclides on an odd isobaric chain except one have a lower-energy neighbor to which they can decay by beta decay. See Mattauch isobar rule.
=== Netherlands === A ban on beak trimming in the Netherlands was first announced in 1996, but due to objections from the poultry sector it was delayed for years. In June 2013, the government struck an agreement between poultry farmers and animal welfare groups to phase out debeaking and prohibit it in 2018. The prohibition on trimming eventually went into effect on 1 January 2019.
Sources: en.wikipedia.org
In a complementary technique, peptide mass fingerprinting involves digestion of the native and modified protein with a protease such as trypsin. This will produce a set of peptides that can be analysed using a mass spectrometer. The peptide that changes in mass after reaction with the inhibitor will be the one that contains the site of modification.
Perhaps the most serious oral condition caused by smoking (including pipe smoking) is oral cancer. However, smoking also increases the risk for various other oral diseases, some almost completely exclusive to tobacco users. Roughly half of periodontitis or inflammation around the teeth cases are attributed to current or former smoking. Smokeless tobacco causes gingival recession and white mucosal lesions. Up to 90% of periodontitis patients who are not helped by common modes of treatment are smokers. Smokers have significantly greater loss of bone height than non-smokers, and the trend can be extended to pipe smokers to have more bone loss than non-smokers. Smoking traditional cigarettes, e-cigarettes, and heat-not-burn products also affects the salivary cytokine levels needed in immune responses. Traditional cigarettes slightly intensify the immune response in long-term smokers compared to non-smokers, with long-term smokers showing higher levels of IFN-γ than non-smokers. E-cigarettes and heat-not-burn products, while marketed as a healthier alternative, have been shown to inhibit immune response function. Users of these products show lower levels of salivary cytokines, chemokines, and growth factors that function to keep the immune response strong and active in the mouth. Smoking has been proven to be an important factor in teeth staining. Halitosis or bad breath is common among tobacco smokers. Tooth loss is 2 to 3 times higher in smokers than in non-smokers.
Gonnet, GH; Cohen, MA; Benner, SA (5 June 1992). "Exhaustive matching of the entire protein sequence database". Science. 256 (5062): 1443–5. doi:10.1126/science.1604319. PMID 1604319. – 1992 work presenting a PAM250 from a larger set of proteins than what Dayhoff had access to Jones, David T.; Taylor, William R.; Thornton, Janet M. (1992). "The rapid generation of mutation data matrices from protein sequences". Bioinformatics. 8 (3): 275–282. doi:10.1093/bioinformatics/8.3.275. – JTT model of 1992, with a clustering process to hopefully reduce the errors from a parismony assumption (i.e. assumption that each observed change happens directly, without intermediate changes; see discussion in doi:10.1093/oxfordjournals.molbev.a003851) Kosiol, Carolin; Goldman, Nick (February 2005). "Different Versions of the Dayhoff Rate Matrix". Molecular Biology and Evolution. 22 (2): 193–199. doi:10.1093/molbev/msi005. – analyses the extant variants of Dayhoff-PAM and proposes Direct Computation with Mutabilities (DCMut) variants of them.
Cyclodextrins were called "cellulosine" when first described by A. Villiers in 1891. Soon after, F. Schardinger identified the three naturally occurring cyclodextrins: α, β, and γ, referred to as "Schardinger sugars". For 25 years, between 1911 and 1935, Hans Pringsheim in Germany was the leading researcher in this area, demonstrating that cyclodextrins formed stable aqueous complexes with many other chemicals. By the mid-1970s, each of the natural cyclodextrins had been structurally and chemically characterized and many more complexes had been studied. Since the 1970s, extensive work has been conducted by Szejtli and others exploring encapsulation by cyclodextrins and their derivatives for industrial and pharmacologic applications. Among the processes used for complexation, the kneading process seems to be one of the best.
Since most of the dissolved CO2 remains as CO2 molecules, Ka1(apparent) has a much larger denominator and a much smaller value than the true Ka1. The bicarbonate ion is an amphoteric species that can act as an acid or as a base, depending on pH of the solution. At high pH, it dissociates significantly into the carbonate ion (CO32–):
Sources: en.wikipedia.org
The sequence corresponds to a fragment of a protein found in human gastric juice, so related sequences are natural. The isolated fifteen-amino-acid peptide supplied for research is produced synthetically. Whether the free fragment circulates naturally in humans has not been settled.
In most jurisdictions it is not an approved medicine and is handled as a research material. Import and sale rules differ by country, and some regulators have placed it in categories that restrict human use. Status can change, so current local rules apply.
Rodent models dominate, particularly rats with induced gastric lesions, tendon injury, or vascular disruption. These designs allow controlled comparison but differ anatomically and metabolically from humans. Results from such models are commonly cited as preliminary.
The lyophilized powder is normally kept at minus twenty degrees Celsius or colder. Solutions are held at refrigerator temperature or below and protected from light. Repeated freezing and thawing is avoided because it can promote aggregation or loss of activity.